TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24305422

Group type: EXPERIMENTAL
Intervention: Novel hydroxyphenoxy propionic acid, ellagic acid, yeast extract, and salicylic acid formulation applied twice daily
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard prescription combination of 4% hydroquinone cream and 0.025% tretinoin cream applied nightly
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Both products (novel formulation and prescription combination)
Number of subjects: 82
Study: 19404314

Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg
Number of subjects: 669

Group type: EXPERIMENTAL
Intervention: Nebivolol 10 mg
Number of subjects: 669

Group type: EXPERIMENTAL
Intervention: Nebivolol 20 mg
Number of subjects: 669

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 669
Study: 18172068

Group type: EXPERIMENTAL
Intervention: Lotrafilcon A (30 night EW)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Lotrafilcon A (DW)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Galyfilcon A (DW)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Lotrafilcon B (6 night EW)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Lotrafilcon B (DW)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: All lens wear (DW, EW)
Number of subjects: 121
Study: 16139808

Group type: EXPERIMENTAL
Intervention: Active repetitive transcranial magnetic stimulation (TMS)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Sham repetitive transcranial magnetic stimulation
Number of subjects: 68
Study: 14616671

Group type: EXPERIMENTAL
Intervention: High stimulation rate (1800 pps/channel)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Moderate stimulation rate (800 pps/channel)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Low stimulation rate (400 pps/channel)
Number of subjects: 11
Study: 11050258

Group type: EXPERIMENTAL
Intervention: Home support
Number of subjects: 184

Group type: COMPARATOR
Intervention: Standard hospital admission
Number of subjects: 184
Study: 9020557

Group type: EXPERIMENTAL
Intervention: Pilocarpine stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spontaneously secreted saliva during radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pilocarpine-treated patients during radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects (no specific intervention mentioned)
Number of subjects: 0
Study: 1544585

Group type: EXPERIMENTAL
Intervention: Low-dose antihypertensive medication (chlorthalidone)
Number of subjects: 4736

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4736
Study: 3933028

Group type: EXPERIMENTAL
Intervention: Lithium carbonate (3-week pretreatment)
Number of subjects: 17

Group type: COMPARATOR
Intervention: d-Amphetamine (20 mg)
Number of subjects: 17
Study: 31895413

Group type: EXPERIMENTAL
Intervention: MaSuRCA assembly
Number of subjects: 1

Group type: COMPARATOR
Intervention: Canu, SMARTdenovo, Flye, Marvel, and MaSuRCA assemblers
Number of subjects: 1
Study: 30257476

Group type: EXPERIMENTAL
Intervention: Brief mental health promotion intervention
Number of subjects: 196
Study: 27329542

Group type: EXPERIMENTAL
Intervention: Testosterone solution 2%
Number of subjects: 715

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 715
Study: 24766637

Group type: EXPERIMENTAL
Intervention: Intensive group‐based upper limb intervention (ULI)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Distributed individualized upper limb intervention (ULI)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Upper limb intervention (ULI)
Number of subjects: 42
Study: 22435740

Group type: EXPERIMENTAL
Intervention: MK-1903 (R,R-19a)
Number of subjects: 0
Study: 20204490

Group type: EXPERIMENTAL
Intervention: Depressive symptoms at the beginning of the year
Number of subjects: 113
Study: 18549463

Group type: EXPERIMENTAL
Intervention: PEG‐IFN alfa‐2b 1.0 micro/kg/week plus RBV 8‐10 mg/kg/day for 24 weeks (group A)
Number of subjects: 53
Study: 15852629

Group type: EXPERIMENTAL
Intervention: Propofol infusion (6.17 +/- 0.98 mg x kg(‐1) x h(‐1)) after delivery
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sevoflurane (1% until delivery)
Number of subjects: 14
Study: 14592306

Group type: EXPERIMENTAL
Intervention: Oral interface (Oracle)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Nasal masks
Number of subjects: 38
Study: 10577755

Group type: EXPERIMENTAL
Intervention: Arthroscopic lysis and lavage (ALL)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Arthroscopic anterolateral capsular release (AALCR)
Number of subjects: 101
Study: 8568290

Group type: EXPERIMENTAL
Intervention: RRV‐TV (tetravalent rhesus-human rotavirus vaccine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RRV‐S1 (monovalent rhesus-human rotavirus vaccine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rotavirus vaccines (both RRV‐S1 and RRV‐TV)
Number of subjects: 0
Study: 1658700

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (0.625 and 1.25 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 7056949

Group type: EXPERIMENTAL
Intervention: RW-Cl (clustered doses of ragweed extract at 3-wk intervals)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: RW-Wk (weekly injections of single doses of ragweed extract)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Rinkel-method immunotherapy
Number of subjects: 44
Study: 31502662

Group type: EXPERIMENTAL
Intervention: Monopolar radiofrequency device with single microneedle, 3 treatments at 4-week intervals
Number of subjects: 63

Group type: COMPARATOR
Intervention: Micro-needling and extraction (Control)
Number of subjects: 63
Study: 30516102

Group type: EXPERIMENTAL
Intervention: T-DM1
Number of subjects: 1486

Group type: COMPARATOR
Intervention: Trastuzumab
Number of subjects: 1486
Study: 30076270

Group type: EXPERIMENTAL
Intervention: 5 mg/day donepezil
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: 5 mg/day donepezil (in apolipoprotein ϵ 4 non-carriers)
Number of subjects: 145
Study: 27381232

Group type: EXPERIMENTAL
Intervention: Enhanced Diabetes Prevention Program (DPP)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Standard Diabetes Prevention Program (DPP)
Number of subjects: 204
Study: 25240072

Group type: EXPERIMENTAL
Intervention: High-energy (HE) beverage (150 kcal)
Number of subjects: 44

Group type: COMPARATOR
Intervention: No-energy (NE) beverage (0 kcal)
Number of subjects: 44
Study: 23000523

Group type: EXPERIMENTAL
Intervention: Simulated Pulpal Pressure (SPP)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Direct Water Exposure (DWE)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Indirect Water Exposure (IWE)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Water Sorption (WS)
Number of subjects: 3
Study: 20089774

Group type: EXPERIMENTAL
Intervention: Lactobacillus salivarius CUL61 and Lactobacillus paracasei CUL08 and Bifidobacterium animalis subsp. lactis CUL34 and Bifidobacterium bifidum CUL20; 1 x 10(10) colony-forming units administered daily during the last month of pregnancy and to infants aged 0-6 months.
Number of subjects: 454

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Both treatment and placebo groups
Number of subjects: 454
Study: 17697906

Group type: EXPERIMENTAL
Intervention: OROS hydromorphone
Number of subjects: 138

Group type: COMPARATOR
Intervention: ER oxycodone
Number of subjects: 138
Study: 16254588

Group type: EXPERIMENTAL
Intervention: Zinc (Zn) supplementation for 6 months
Number of subjects: 433
Study: 12188097

Group type: EXPERIMENTAL
Intervention: Naltrexone (NTX), 50 mg/day
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 10553752

Group type: EXPERIMENTAL
Intervention: D-serine (30 mg/kg per day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8710463

Group type: EXPERIMENTAL
Intervention: Power Doppler sonography (PDS)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional color Doppler sonography (CDS)
Number of subjects: 36
Study: 1852401

Group type: EXPERIMENTAL
Intervention: High and low water content hydrogel lenses
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: After lens removal
Number of subjects: 6
Study: 6851723

Group type: EXPERIMENTAL
Intervention: Heparin-dihydergot 2500 (2 X 2500 IU) with 0.5 mg dihydroergotamine (DHE)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Conventional low dose heparin regimen (2 X 5000 IU)
Number of subjects: 500
Study: 30930187

Group type: EXPERIMENTAL
Intervention: Active tRNS (n = 8)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sham tRNS (n = 11)
Number of subjects: 19
Study: 29194080

Group type: EXPERIMENTAL
Intervention: Harmonic Intonation (HI) test
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Disharmonic Intonation (DI) test
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Italian Sentence Test with Adaptive Randomized Roving level (STARR) test
Number of subjects: 43

Group type: COMPARATOR
Intervention: Bimodal listening
Number of subjects: 43

Group type: COMPARATOR
Intervention: CI-only condition
Number of subjects: 43
Study: 26569165

Group type: EXPERIMENTAL
Intervention: Green tea beverages with low catechin content (149.5 mg catechins with a galloyl moiety)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Green tea beverages with high catechin content (246.5 mg catechins with a galloyl moiety)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo (green tea beverages without catechins)
Number of subjects: 126
Study: 25012418

Group type: EXPERIMENTAL
Intervention: SSRI (escitalopram or citalopram) or dual therapy (serotonergic agent)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: bupropion
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Combined index of word fluency and RT
Number of subjects: 70
Study: 22398243

Group type: EXPERIMENTAL
Intervention: MVA-mBN32 vaccine after first immunization
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: MVA-mBN32 vaccine after second immunization
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: MVA-mBN32 vaccine
Number of subjects: 36
Study: 20104460

Group type: EXPERIMENTAL
Intervention: Milrinone (50 microg/kg bolus followed by 0.5 microg/kg/min infusion for 24 hours)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 70
Study: 17568299

Group type: EXPERIMENTAL
Intervention: Acupuncture (ACU)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral therapy (CBT)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Wait-list control (WLC)
Number of subjects: 47
Study: 16248851

Group type: EXPERIMENTAL
Intervention: Phenserine tartrate 10 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Phenserine tartrate 5 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Phenserine tartrate 20 mg
Number of subjects: 32
Study: 12137863

Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg daily on days 5‐9 after menses
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate 50 mg daily on days 5‐9 after menses
Number of subjects: 19

Group type: COMPARATOR
Intervention: Natural cycles (control)
Number of subjects: 19
Study: 11770918

Group type: EXPERIMENTAL
Intervention: Cranial clock slides (Group C)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Traditional text slides (Group T)
Number of subjects: 21
Study: 9594511

Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure (PEEP) 10 cmH2O during nitrous oxide elimination
Number of subjects: 39

Group type: COMPARATOR
Intervention: No positive end-expiratory pressure (PEEP) during nitrous oxide elimination
Number of subjects: 39
Study: 7993190

Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) administration of recombinant human erythropoietin (rhEPO) at a median dose of 33 U/kg body weight three times a week
Number of subjects: 90

Group type: COMPARATOR
Intervention: Subcutaneous (SC) administration of recombinant human erythropoietin (rhEPO) at a median dose of 22 U/kg body weight
Number of subjects: 90

Group type: COMPARATOR
Intervention: Subcutaneous (SC) administration of rhEPO
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) administration of rhEPO
Number of subjects: 90
Study: 2687357

Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (DHE) 15 micrograms/kg
Number of subjects: 9
Study: 1212026

Group type: EXPERIMENTAL
Intervention: 2 mg of glucagon
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6783023

Group type: EXPERIMENTAL
Intervention: Sodium valproate (1200 mg daily for one week)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control (multivitamins and fluid/electrolyte replacement, some received chlormethiazole or other tranquillisers)
Number of subjects: 49
Study: 30188220

Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice (BRJ; 12.9 mmol)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Nitrate-depleted beetroot juice (PL; 0.5 mmol)
Number of subjects: 8
Study: 30007519

Group type: EXPERIMENTAL
Intervention: Automated VR treatment (delivered in roughly six 30‐min sessions over a 2‐week period)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 100
Study: 26518514

Group type: EXPERIMENTAL
Intervention: 1250 mg/day omega‐3 fatty acid + vitamin E placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 400 IU/day vitamin E + omega‐3 fatty acids placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 1250 mg omega‐3 fatty acids/day + 400 IU/day vitamin E
Number of subjects: 120

Group type: COMPARATOR
Intervention: omega‐3 fatty acids placebo + vitamin E placebo
Number of subjects: 120
Study: 24999060

Group type: EXPERIMENTAL
Intervention: Long-term medication assisted treatment (LT-MAT) with buprenorphine/naloxone (BUP/NX)
Number of subjects: 1036

Group type: COMPARATOR
Intervention: Short-term medication assisted treatment (ST-MAT) with buprenorphine/naloxone (BUP/NX)
Number of subjects: 1036

Group type: EXPERIMENTAL
Intervention: Both LT-MAT and ST-MAT with buprenorphine/naloxone (BUP/NX)
Number of subjects: 1036
Study: 22836073

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 80 mg once weekly
Number of subjects: 20

Group type: COMPARATOR
Intervention: Atorvastatin 10 mg daily
Number of subjects: 20
Study: 20598959

Group type: EXPERIMENTAL
Intervention: US-guided pes anserinus bursa injections
Number of subjects: 24

Group type: COMPARATOR
Intervention: Unguided pes anserinus bursa injections
Number of subjects: 24
Study: 17645718

Group type: EXPERIMENTAL
Intervention: T tube
Number of subjects: 107

Group type: COMPARATOR
Intervention: No T tube
Number of subjects: 107
Study: 16231339

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 158

Group type: COMPARATOR
Intervention: Interpersonal therapy
Number of subjects: 158
Study: 12411528

Group type: EXPERIMENTAL
Intervention: Calcium channel blocker (CCB), amlodipine, administered for 7 days prior to and for 7 days following the damage protocol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium channel blocker (CCB), amlodipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10221356

Group type: EXPERIMENTAL
Intervention: Zolpidem (15mg/70kg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 7860392

Group type: EXPERIMENTAL
Intervention: Interdigitating chemotherapy and radiotherapy (COPE followed by thoracic radiation therapy)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Concurrent chemotherapy and radiotherapy (DDP and etoposide with concurrent thoracic radiation therapy)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI) after completion of chemotherapy
Number of subjects: 61

Group type: COMPARATOR
Intervention: Esophagitis
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Hematologic and pulmonary toxicity
Number of subjects: 61
Study: 1934001

Group type: EXPERIMENTAL
Intervention: Health education program (experimental group)
Number of subjects: 453

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 453
Study: 6127851

Group type: EXPERIMENTAL
Intervention: Phenazepam + Sydnocarb
Number of subjects: 102

Group type: COMPARATOR
Intervention: Phenazepam alone
Number of subjects: 102
Study: 31903865

Group type: EXPERIMENTAL
Intervention: Thyroid hormone treatment in euthyroid women with thyroid autoimmunity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radioactive iodine (RAI) treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thyroid hormone treatment for TSH >4 mIU/L
Number of subjects: 0
Study: 30740877

Group type: EXPERIMENTAL
Intervention: Topical phenytoin 2% powder spray
Number of subjects: 60

Group type: COMPARATOR
Intervention: Regular sitz baths only
Number of subjects: 60
Study: 30049503

Group type: EXPERIMENTAL
Intervention: Morphine ARER 100 mg
Number of subjects: 49

Group type: COMPARATOR
Intervention: Extended-release morphine 100 mg
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 49
Study: 26864458

Group type: EXPERIMENTAL
Intervention: Echocardiographically measured epicardial fat thickness (EFT)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Echocardiographically measured EFT
Number of subjects: 234
Study: 25130704

Group type: EXPERIMENTAL
Intervention: RBC transfusion
Number of subjects: 519

Group type: COMPARATOR
Intervention: Non-intervention
Number of subjects: 519
Study: 21558456

Group type: EXPERIMENTAL
Intervention: Saquinavir-boosted ritonavir at therapeutic dose (1000/100 mg bid)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Saquinavir-boosted ritonavir at supratherapeutic dose (1500/100 mg bid)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4

Group type: COMPARATOR
Intervention: Positive control (moxifloxacin 400 mg)
Number of subjects: 4
Study: 21097481

Group type: EXPERIMENTAL
Intervention: RADPAD
Number of subjects: 22

Group type: COMPARATOR
Intervention: No RADPAD
Number of subjects: 22
Study: 17531335

Group type: EXPERIMENTAL
Intervention: Combined schedule of external beam treatment (35.75 Gy in 13 fractions) followed by high dose rate brachytherapy (17 Gy in two fractions)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Standard radiotherapy (55 Gy in 20 fractions)
Number of subjects: 220
Study: 16366808

Group type: EXPERIMENTAL
Intervention: Brief Relationship Therapy (BRT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard Behavioral Couples Therapy (S-BCT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Individual-Based Treatment (IBT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Psychoeducational Attention Control Treatment (PACT)
Number of subjects: 100
Study: 12459616

Group type: EXPERIMENTAL
Intervention: Atraumatic restorative treatment (ART)
Number of subjects: 12
Study: 10418023

Group type: EXPERIMENTAL
Intervention: Continuous infusion of cefepime (Group 1, n = 9)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Intermittent infusion of cefepime (Group 2, n = 9)
Number of subjects: 18
Study: 7739307

Group type: EXPERIMENTAL
Intervention: Intravenous heparin infusion (partial thromboplastin time 1.5‐2 times baseline)
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin (adjusted dose with partial thromboplastin time 1.5‐2 times baseline)
Number of subjects: 343

Group type: COMPARATOR
Intervention: Aspirin (325 mg daily)
Number of subjects: 343
Study: 2298592

Group type: EXPERIMENTAL
Intervention: 200 or 400 ml ice water ingestion
Number of subjects: 89
Study: 373836

Group type: EXPERIMENTAL
Intervention: Ioxaglate
Number of subjects: 61

Group type: COMPARATOR
Intervention: Diatrizoate (Urografin 60%)
Number of subjects: 61
Study: 29902234

Group type: EXPERIMENTAL
Intervention: 4% chlorhexidine cord application
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Health messages disseminated by ZamCAT field monitors
Number of subjects: 36
Study: 26163337

Group type: EXPERIMENTAL
Intervention: CHO supplementation during exercise (Ex-CHO)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Placebo supplementation during exercise (Ex-PLA)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Resting control group (CON)
Number of subjects: 32
Study: 24886235

Group type: EXPERIMENTAL
Intervention: STAIR Narrative Therapy
Number of subjects: 352

Group type: COMPARATOR
Intervention: Treatment As Usual (TAU)
Number of subjects: 352
Study: 22246687

Group type: EXPERIMENTAL
Intervention: early locomotor training (early-LTP) initiated 2 months poststroke
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: late locomotor training (late-LTP) initiated 6 months poststroke
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: home exercise
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Berg Balance Scale score ≤ 42/56
Number of subjects: 408
Study: 20616218

Group type: EXPERIMENTAL
Intervention: High-resolution single nucleotide polymorphism mapping array analysis
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: U133 Plus 2.0 expression array (Affymetrix)
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Fluorescence in situ hybridization and expression quartile analysis
Number of subjects: 372
Study: 18579575

Group type: EXPERIMENTAL
Intervention: Long-term antidepressant medication in patients with MDD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acute administration of citalopram to controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation of abnormal signals in MDD
Number of subjects: 0
Study: 16104964

Group type: EXPERIMENTAL
Intervention: Piezoelectric device (PS)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Conventional rotating drills (RD)
Number of subjects: 69
Study: 12075396

Group type: COMPARATOR
Intervention: Diltiazem
Number of subjects: 41

Group type: COMPARATOR
Intervention: Esmolol
Number of subjects: 41

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 41
Study: 9927101

Group type: EXPERIMENTAL
Intervention: 5-mg pilocarpine tablets (20 mg/d)
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: 2.5-mg pilocarpine tablets
Number of subjects: 373

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 373
Study: 7752293

Group type: EXPERIMENTAL
Intervention: Therapy coupled with urine monitoring
Number of subjects: 0
Study: 2196772

Group type: EXPERIMENTAL
Intervention: DL‐diltiazem (0.4 mg/kg as a bolus intravenously, followed by an infusion of 15 mg/hr)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 7002375

Group type: EXPERIMENTAL
Intervention: Myringotomy with adenoidectomy
Number of subjects: 42

Group type: COMPARATOR
Intervention: Myringotomy without adenoidectomy
Number of subjects: 42